Ulta Beauty Inc. (ULTA) Q2 (USD) EPS 6.55 (exp. 6.19), Revenue 3.04bln (exp. 2.98bln),
Newsquawk Staff ·
Raises FY26 Adj. EPS view to USD 28.70-29.00 (exp. 28.77)
What it means
A clean beat on both lines with the guidance raise bracketing rather than clearing consensus, which is the distinction that matters here: when a raised range's midpoint lands at or near the existing Street view, the market has historically treated the print as confirmation rather than acceleration, and initial strength has tended to fade into questions about what was left out of the guide. For this name, the recurring drivers in past cycles have been comparable sales composition, traffic versus ticket, and margin absorption from shrink and wage costs; the headline EPS line has often mattered less than the comp and gross margin detail that follows in the release and on the call. The guidance mechanics are worth scrutiny on form: whether the raise is pulled forward from H1 outperformance or reflects genuine H2 confidence, a split that has determined follow-through in comparable retail prints. The peer read-through runs through the beauty and prestige consumer cohort, where this issuer has often traded as the category bellwether. The immediate tells are the comp cadence, commentary on promotional intensity, and whether management's tone on the consumer matches prior cautious framing.
- Texas Attorney General Ken Paxton sues OpenAI and CEO Sam Altman for lying to users and harming Texans
- Daily US Earnings Estimates: 26th October 2026: VZ, WELL
- Moonshot AI unveils 2.8tln-parameter Kimi K3.1 Pro model; says it beats Opus 5.5 and GPT-6 Astra on long-horizon coding tasks and scores top marks on SWE Marathon and agent benchmarks; pledges open weights for the 3tln-class model by November 4th
- The Trump administration plans to introduce voluntary “US Caught Seafood” labels to help consumers identify seafood origins, according to CBS
- Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 2027
Related headlines
- OpenAI reveals plans for an in-house exabyte-scale storage system3 hours ago
- Republican Senator Blackburn has raised concerns about Meta’s (META) plans to update its commercial terms, warning that the changes could “exploit American creators and businesses,” according to a letter3 hours ago
- Upside in Penguin Solutions (PEGN) attributed to M&A chatter - UNCONFIRMED 3 hours ago
- CrowdStrike (CRWD) CEO says in the coming months we will see a lot of breaches from the PHP vulnerability3 hours ago
- US President Trump says Elon Musk will not do anything wrong regarding access to Starlink (SPCX) in Ukraine3 hours ago
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)4 hours ago
- Ukraine President Zelensky says the Tesla (TSLA)/SpaceX (SPCX) Starlink and Starshield service remains slowed4 hours ago
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce5 hours ago
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders5 hours ago
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer5 hours ago
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation6 hours ago
- American Express (AXP) to cut 5% of jobs6 hours ago
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM6 hours ago
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years7 hours ago
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months7 hours ago